InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (4 ops.)
Insider track record
OtherDisclosed buys
0
Disclosed sells
4
T+90 hit rate
0%
T+90 mean return
-27.9%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by DEKKERS MARIJN E. Insider active across 4 companies, notably Quanterix Corp. Cumulatively, 18 disclosures have been published. Breakdown: 0 buy · 4 sells. Total volume traded: €8.4m. Activity tracked since 4 June 2021. The latest transaction was disclosed on 16 May 2024 (Cession). Regulator: SEC (Form 4). The full history is openly available.
Declarations18 total
31,822 sharesCommon StockSEC:0000950170-24-090815:0
105,263 sharesClass A Common StockSEC:0001127602-24-018709:0
10,461 sharesCommon StockSEC:0000950170-24-070735:0
265,000 shares@ US$0.83039.5% of flowClass A Common StockSEC:0001127602-24-015998:0
1,727,056 shares@ US$0.9369.6% of flowClass A Common StockSEC:0001127602-24-015293:0
200,000 shares@ US$34.43100.0% of flowCommon StockSEC:0000950170-23-028968:0
3,282 sharesCommon StockSEC:0000899243-23-015176:0
171,455 shares@ US$2.5620.9% of flowClass A Common StockSEC:0000899243-22-035326:0
70,921 shares0Class A Common StockSEC:0000899243-22-022291:0
1,746,706 shares0Class A Common StockSEC:0000899243-22-010987:0
14,270 sharesCommon StockSEC:0000899243-21-038068
14,270 sharesCommon StockSEC:0000899243-21-038068:0
374,960 sharesClass A Common StockSEC:0000899243-21-036672:0
374,960 sharesClass A Common StockSEC:0000899243-21-036672
500,000 shares@ US$10.0050.0% of flowClass A Common StockSEC:0001104659-21-080928
500,000 shares@ US$10.0050.0% of flowClass A Common StockSEC:0001104659-21-080928:0
1,951 shares@ US$8.160.010% mcap50.0% of flowCommon StockSEC:0001562180-21-004128:0
1,951 shares@ US$8.1650.0% of flowCommon StockSEC:0001562180-21-004128
18 of 18 declarations
About DEKKERS MARIJN E
DEKKERS MARIJN E is a director at Quanterix Corp, and also holds positions at Quantum-Si Inc, Ginkgo Bioworks Holdings, Inc., and Cerevel Therapeutics Holdings, Inc.
